Cargando…
The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma
Early detection improves survival and increases curative probability in hepatocellular carcinoma (HCC). Peripheral blood mononuclear cells (PBMCs) can provide an inexpensive, less-invasive and highly accurate method. The objective of this study is to find the potential marker for HCC screening, util...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295309/ https://www.ncbi.nlm.nih.gov/pubmed/34290294 http://dx.doi.org/10.1038/s41598-021-94330-1 |
_version_ | 1783725406367514624 |
---|---|
author | Patarat, Rathasapa Riku, Shoji Kunadirek, Pattapon Chuaypen, Natthaya Tangkijvanich, Pisit Mutirangura, Apiwat Puttipanyalears, Charoenchai |
author_facet | Patarat, Rathasapa Riku, Shoji Kunadirek, Pattapon Chuaypen, Natthaya Tangkijvanich, Pisit Mutirangura, Apiwat Puttipanyalears, Charoenchai |
author_sort | Patarat, Rathasapa |
collection | PubMed |
description | Early detection improves survival and increases curative probability in hepatocellular carcinoma (HCC). Peripheral blood mononuclear cells (PBMCs) can provide an inexpensive, less-invasive and highly accurate method. The objective of this study is to find the potential marker for HCC screening, utilizing gene expression of the PBMCs. Data from the NCBI GEO database of gene expression in HCC patients and healthy donor's PBMCs was collected. As a result, GSE 49515 and GSE 58208 were found. Using both, a statistical significance test was conducted in each gene expression of each data set which resulted in 187 genes. We randomized three selected genes (FLNA, CAP1, and CLU) from the significant p-value group (p-values < 0.001). Then, a total of 76 healthy donors, 153 HCC, 20 hepatic fibrosis, 20 non-alcoholic fatty liver were collected. Quantitative RT-PCR (qRT-PCR) was performed in cDNA from all blood samples from the qRT-PCR, The Cycle threshold (Ct) value of FLNA, CLU, CAP1 of HCC group (28.47 ± 4.43, 28.01 ± 3.75, 29.64 ± 3.90) were lower than healthy group (34.23 ± 3.54, 32.90 ± 4.15, 32.18 ± 5.02) (p-values < 0.0001). The accuracy, sensitivity and specificity of these genes as a screening tool were: FLNA (80.8%, 88.0%, 65.8%), CLU (63.4%, 93.3%, 31.3%), CAP1 (67.2%, 83.3%, 39.1%). The tests were performed in two and three gene combinations. Results demonstrated high accuracy of 86.2%, sensitivity of 85% and specificity of 88.4% in the FLNA and CLU combination. Furthermore, after analyzed using hepatic fibrosis and non-alcoholic fatty liver as a control, the FLNA and CLU combination is shown to have accuracy of 76.9%, sensitivity of 77.6% and specificity of 75%. Also, we founded that our gene combination performs better than the current gold standard for HCC screening. We concluded that FLNA and CLU combination have high potential for being HCC novel markers. Combined with current tumor markers, further research of the gene’s expression might help identify more potential markers and improve diagnosis methods. |
format | Online Article Text |
id | pubmed-8295309 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-82953092021-07-22 The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma Patarat, Rathasapa Riku, Shoji Kunadirek, Pattapon Chuaypen, Natthaya Tangkijvanich, Pisit Mutirangura, Apiwat Puttipanyalears, Charoenchai Sci Rep Article Early detection improves survival and increases curative probability in hepatocellular carcinoma (HCC). Peripheral blood mononuclear cells (PBMCs) can provide an inexpensive, less-invasive and highly accurate method. The objective of this study is to find the potential marker for HCC screening, utilizing gene expression of the PBMCs. Data from the NCBI GEO database of gene expression in HCC patients and healthy donor's PBMCs was collected. As a result, GSE 49515 and GSE 58208 were found. Using both, a statistical significance test was conducted in each gene expression of each data set which resulted in 187 genes. We randomized three selected genes (FLNA, CAP1, and CLU) from the significant p-value group (p-values < 0.001). Then, a total of 76 healthy donors, 153 HCC, 20 hepatic fibrosis, 20 non-alcoholic fatty liver were collected. Quantitative RT-PCR (qRT-PCR) was performed in cDNA from all blood samples from the qRT-PCR, The Cycle threshold (Ct) value of FLNA, CLU, CAP1 of HCC group (28.47 ± 4.43, 28.01 ± 3.75, 29.64 ± 3.90) were lower than healthy group (34.23 ± 3.54, 32.90 ± 4.15, 32.18 ± 5.02) (p-values < 0.0001). The accuracy, sensitivity and specificity of these genes as a screening tool were: FLNA (80.8%, 88.0%, 65.8%), CLU (63.4%, 93.3%, 31.3%), CAP1 (67.2%, 83.3%, 39.1%). The tests were performed in two and three gene combinations. Results demonstrated high accuracy of 86.2%, sensitivity of 85% and specificity of 88.4% in the FLNA and CLU combination. Furthermore, after analyzed using hepatic fibrosis and non-alcoholic fatty liver as a control, the FLNA and CLU combination is shown to have accuracy of 76.9%, sensitivity of 77.6% and specificity of 75%. Also, we founded that our gene combination performs better than the current gold standard for HCC screening. We concluded that FLNA and CLU combination have high potential for being HCC novel markers. Combined with current tumor markers, further research of the gene’s expression might help identify more potential markers and improve diagnosis methods. Nature Publishing Group UK 2021-07-21 /pmc/articles/PMC8295309/ /pubmed/34290294 http://dx.doi.org/10.1038/s41598-021-94330-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Patarat, Rathasapa Riku, Shoji Kunadirek, Pattapon Chuaypen, Natthaya Tangkijvanich, Pisit Mutirangura, Apiwat Puttipanyalears, Charoenchai The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma |
title | The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma |
title_full | The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma |
title_fullStr | The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma |
title_full_unstemmed | The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma |
title_short | The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma |
title_sort | expression of flna and clu in pbmcs as a novel screening marker for hepatocellular carcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295309/ https://www.ncbi.nlm.nih.gov/pubmed/34290294 http://dx.doi.org/10.1038/s41598-021-94330-1 |
work_keys_str_mv | AT pataratrathasapa theexpressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma AT rikushoji theexpressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma AT kunadirekpattapon theexpressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma AT chuaypennatthaya theexpressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma AT tangkijvanichpisit theexpressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma AT mutiranguraapiwat theexpressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma AT puttipanyalearscharoenchai theexpressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma AT pataratrathasapa expressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma AT rikushoji expressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma AT kunadirekpattapon expressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma AT chuaypennatthaya expressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma AT tangkijvanichpisit expressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma AT mutiranguraapiwat expressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma AT puttipanyalearscharoenchai expressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma |